Abstract P309: N-3 Polyunsaturated Fatty Acids and Subclinical Atherosclerosis in Mexican Women
Introduction: Long chain n-3 polyunsaturated fatty acids (n-3 PUFAs) may affect cardiovascular risk through various biological pathways. There is limited evidence of the relation with subclinical atherosclerosis (SA).
Hypothesis: N-3 PUFAs is inversely associated with SA.
Methods: We evaluated the cross-sectional association between whole blood eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and common carotid intima media thickness (cIMT) in 490 disease-free without self-reported hypertension, diabetes, hypercholesterolemia, stroke, myocardial infarction, and/or peripheral arterial disease women in the Mexican Teachers’ Cohort from Chiapas and Yucatan. Between 2012 and 2013, neurologists assessed cIMT with an ultrasound and we measured whole blood EPA+DPA through HPLC in dried blood spots and expressed values as % of total identified fatty acids. In a reproducibility study we observed an intraclass correlation coefficient of 0.89 (n=52). We categorized whole blood EPA+DHA in quartiles and defined SA as cIMT ≥0.8mm or presence of plaque. Mean adjusted differences and multivariable odds ratios with the lowest category as a reference were estimated using linear and logistic regression.
Results: Mean (±SD) age was 46.5 (±7.7) and the prevalence of SA was 18.8% (n=92). Mean %EPA+DHA was 3.65±0.83 and the prevalence of low %EPA+DHA (below 4%) was 71%. In multivariable analyses (Table), we observed a suggestion of an inverse relation with %DHA but results were not statistically significant. The mean adjusted difference (95%CI) comparing extreme quartiles of %DHA was -0.018(-0.039 - 0.003), p-trend 0.17. The OR(95%CI) comparing extreme quartiles of %DHA was 0.59(0.27-1.27).
Conclusions: In a population of middle-aged Mexican women whole blood EPA and DHA were not associated to intima-media thickness. The narrow distribution of N-3 PUFA levels in this population may have limited our ability to detect an association.
Author Disclosures: A. Monge: None. E. Ortiz-Panozo: None. E. Yunes: None. C. Cantu-Brito: None. A. Catzin-Khulmann: None. R. Lopez-Ridaura: B. Research Grant; Modest; Non-restricted investigator-initiated grant from AstraZeneca. W.S. Harris: A. Employment; Significant; Health Diagnostic Laboratory, Inc.. F. Ownership Interest; Significant; OmegaQuant Analytics, LLC. G. Consultant/Advisory Board; Significant; Aker Biomarine. M. Lajous: B. Research Grant; Modest; Non-restricted investigator-initiated grant from AstraZeneca.
- © 2015 by American Heart Association, Inc.